Lehman Upgrades Regeneron Pharmaceuticals
Lehman Brothers upgraded Regeneron Pharmaceuticals (REGN ) to overweight from equal-weight. It also raised its $9 price target to $19.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.